Compare · NLTX vs NVO
NLTX vs NVO
Side-by-side comparison of Neoleukin Therapeutics Inc. (NLTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NLTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 1265.5x NLTX ($151.0M).
- NVO has hit the wire 8 times in the past 4 weeks while NLTX has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 2 for NLTX).
- Company
- Neoleukin Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $13.96+298.86%
- $44.01+2.84%
- Market cap
- $151.0M
- $191.15B
- 1M return
- -
- -6.46%
- 1Y return
- -
- -44.17%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 0
- 8
- Recent ratings
- 2
- 25
Neoleukin Therapeutics Inc.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NLTX
- SEC Form SC 13G filed by Neoleukin Therapeutics Inc.
- SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)
- SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)
- SEC Form SC 13G filed by Neoleukin Therapeutics Inc.
- SEC Form SC 13G filed by Neoleukin Therapeutics Inc.
- SEC Form SC 13G filed by Neoleukin Therapeutics Inc.
- SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)
- SEC Form 144 filed by Neoleukin Therapeutics Inc.
- SEC Form 4 filed by Woods Robert Keith
- SEC Form 4 filed by Palekar Rohan
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care